Antiphospholipid syndrome pathophysiology
Jump to navigation
Jump to search
|
Antiphospholipid syndrome Microchapters |
|
Differentiating Antiphospholipid syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Antiphospholipid syndrome pathophysiology On the Web |
|
American Roentgen Ray Society Images of Antiphospholipid syndrome pathophysiology |
|
Risk calculators and risk factors for Antiphospholipid syndrome pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Feham Tariq, MD [2]
Overview
Antiphospholipid syndrome (APS) is an autoimmune disease in which antiphospholipid antibodies (anti-cardiolipin antibodies and lupus anticoagulant) react against proteins that bind to anionic phospholipids on plasma membranes. This syndrome can be classified into primary (no underlying disease state) and secondary (in association with an underlying disease state) types. The underlying mechanism of APS mediated by the antibodies is mainly mediated via their affect on the coagulation cascade which subsequenlty leads to increased vascular tone of thrombosis. CAPS is a subclass of APS that results in development of a catastrophic illness characterized by progressive, severe arterial and venous thrombosis in multiple organs, often leading to death.
Pathophysiology
The pathogenesis of antiphospholipid syndrome is as follows:[1][2]
- It is a non-inflammatory autoimmune disease, in which antiphospholipid antibodies react against proteins that bind to anionic phospholipids on plasma membranes.
- APS can be classified into two types based on the underlying cause.
- Primary APS
- Secondary APS
Primary APS
This type of APS has no other associated condition.
Secondary APS
The type of APS which occurs secondary to an underlying disease. The diseases and conditions associated with APS are as follows:[3][4][5]
| Autoimmune diseases | Infections | Drugs | Malignancy |
|---|---|---|---|
|
Bacterial infections:
Viral infections:
Parasitic infections:
|
Tumors of the following organs can cause APS:
Cancers: |
Types of antiphospholipid antibodies
The following antiphospholipid antibodies are found in the plasma of patients:
| Antiphospholipid antibodies | Percentage |
|---|---|
| Anticardiolipin antibody | 31% |
| Lupus anticoagulant (LA) | 23-47% |
| Anti-beta-2 glycoprotein I | 20% |
Mechanism of action
The mechanism by which clinical manifestations occur in APS is mainly mediated by the antibodies which is as follows: [9][10][11][12][13][14][15]
Vascular thrombosis
- Antiphospholipid antibody (aPL) affects the coagulation cascade.
- They have a procoagulant action on the following proteins and tissue factors in the plasma:
- Protein C
- Annexin V
- Platelets
- Serum proteases
- Toll-like receptors
- Tissue factor, and via impaired fibrinolysis
- The cumulative procoagulant effect of these, leads to vascular thrombosis.
Increased vascular tone:
Another effect of aPL is increased vascular tone which subsequently results in the following manifestations:
- Neurological abnormalities such as stroke and transient ischemic attack
- Fetal loss
- Atherosclerosis
Role of Antiphospholipid Antibodies:
These antibodies have the following mechanism of action:[16][17][18][18]
- Anti-beta-2 glycoprotein I antibody enhances the anticoagulant function of protein S by interfering its binding to its inhibitor C4b binding protein.
- They bind negatively charged phospholipids and inhibit contact activation of the clotting cascade and platelet activation.
- Another mechanism by which antiphospholipid antibodies create a prothrombotic state is by developing acquired activated protein C resistance.
Cellular mechanism
The underlying cellular mechanism involved in the pathogenesis of APS in as follows:[19][20][21]
- Monocytes, platelets, endothelial cells and complement play an important role in induction of thrombosis and fetal death in antiphospholipid syndrome.
- APS antibodies such as anti-β2-glycoprotein-1 activate endothelial cells and monocytes.
- In turn, endothelial cells express the following adhesion molecules:
- Intercellular cell adhesion molecule-1
- Vascular cell adhesion molecule-1
- E-selectin
- Both endothelial cells and monocytes upregulate the production of tissue factor which activates the coagulation pathway.
- Activated platelets increase expression of glycoprotein IIb/IIIa and synthesis of thromboxane A2.
- Nuclear factor κB (NFκB) and p38 mitogen-activated protein kinase (p38 MAPK) are important mediators of these three processes.
- Complement activation play a pivotal role in thrombosis and fetal loss induced by antiphospholipid antibodies.
- C3b fragments are deposited in the placentas of patients with antiphospholipid syndrome.
Microparticles
- Microparticles are found in the plasma of patients with APS in elevated levels.[22][23]
- These are cell surface fragments released from the damaged, apoptotic and dying cells.
- They lead to cell activation and subsequently lead to a prothrombotic state in the plasma.
Catastrophic Antiphospholipid Antibody Syndrome (CAPS)
- CAPS is a subclass of APS that results in development of a catastrophic illness characterized by progressive, severe arterial and venous thrombosis in multiple organs, often leading to death.
- Classification criteria for CAPS is as follows:
| Classification criteria for CAPS | ||||
|---|---|---|---|---|
| Criteria | ||||
| ||||
| Classification | ||||
Definite CAPS
| ||||
Probable CAPS
|
- Commonly involved organs include the central nervous system (CNS), kidney and distal extremities with acral necrosis. Hypertension is also commonly present, and may be malignant.
- CNS manifestations may be quite heterogeneous, including confusion, focal signs, and/or seizures.
- Acute Respiratory Distress Syndrome (ARDS) may be present
- Adrenal hemorrhage
- Liver and gastrointestinal tract infarctions
- Oliguria and rapidly deteriorating renal function.
- Commonly involved organs include the central nervous system (CNS), kidney and distal extremities with acral necrosis. Hypertension is also commonly present, and may be malignant.
Genetic association
Antiphospholipid antibody syndrome is associated with the following genetic mutations:[24][25]
Gross Pathology Findings
Microscopic Pathology Findings
Histologic studies of skin or other involved tissues reveal the following:
- A noninflammatory bland thrombosis with no signs of perivascular inflammation or leukocytoclastic vasculitis.
- Biopsy samples from affected kidneys demonstrate glomerular and small arterial microthrombi.
- Histopathology findings in CAPS shows evidence of multiple small and/or large vessel occlusions.
References
- ↑ Negrini S, Pappalardo F, Murdaca G, Indiveri F, Puppo F (2017). "The antiphospholipid syndrome: from pathophysiology to treatment". Clin Exp Med. 17 (3): 257–267. doi:10.1007/s10238-016-0430-5. PMID 27334977.
- ↑ Giannakopoulos B, Krilis SA (2013). "The pathogenesis of the antiphospholipid syndrome". N Engl J Med. 368 (11): 1033–44. doi:10.1056/NEJMra1112830. PMID 23484830.
- ↑ Taraborelli M, Leuenberger L, Lazzaroni MG, Martinazzi N, Zhang W, Franceschini F; et al. (2016). "The contribution of antiphospholipid antibodies to organ damage in systemic lupus erythematosus". Lupus. 25 (12): 1365–8. doi:10.1177/0961203316637431. PMID 26945023.
- ↑ Conti F, Ceccarelli F, Perricone C, Leccese I, Massaro L, Pacucci VA; et al. (2016). "The chronic damage in systemic lupus erythematosus is driven by flares, glucocorticoids and antiphospholipid antibodies: results from a monocentric cohort". Lupus. 25 (7): 719–26. doi:10.1177/0961203315627199. PMID 26821965.
- ↑ Love PE, Santoro SA (1990). "Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance". Ann Intern Med. 112 (9): 682–98. PMID 2110431.
- ↑ McNeil HP, Chesterman CN, Krilis SA (1991). "Immunology and clinical importance of antiphospholipid antibodies". Adv Immunol. 49: 193–280. PMID 1853785.
- ↑ Safa O, Crippa L, Della Valle P, Sabbadini MG, Viganò D'Angelo S, D'Angelo A (1999). "IgG reactivity to phospholipid-bound beta(2)-glycoprotein I is the main determinant of the fraction of lupus anticoagulant activity quenched by addition of hexagonal (II) phase phospholipid in patients with the clinical suspicion of antiphospholipid-antibody syndrome". Haematologica. 84 (9): 829–38. PMID 10477458.
- ↑ Triplett DA (1998). "Many faces of lupus anticoagulants". Lupus. 7 Suppl 2: S18–22. PMID 9814666.
- ↑ Bick, RL, et al. Antiphospholipid and thrombosis syndromes. Sem Thromb and Hemostasis 1994;20:3. PMID 8059232
- ↑ Cervera, R, et al. Clinicopathologic correlations of the antiphospholipid syndrome. Sem Arth and Rheum 1995;24:262. PMID 7740306
- ↑ Kampe, CE. Clinical syndromes associated with lupus anticoagulants. Sem Thromb and Hemostasis 1994;20:16. PMID 8059230
- ↑ Asherson, RA. The catastrophic antiphospholipid antibody syndrome. J Rheum 1992:19:508. PMID 1593568
- ↑ Ruffatti, A, et al. A catastrophic antiphospholipid antibody syndrome: the importance of high levels of warfarin anticoagulation. J Int Med 1994;325:81.PMID8283165
- ↑ Neuwelt, CM, et al. Catastrophic antiphospholipid syndrome: Response to repeated plasmapheresis. A&R 1997;40:1534. PMID 9259436
- ↑ Bermas, BL, et al. Prognosis and therapy of antiphospholipid antibody syndrome. UpToDate 1997.
- ↑ Merrill JT, Zhang HW, Shen C, Butman BT, Jeffries EP, Lahita RG; et al. (1999). "Enhancement of protein S anticoagulant function by beta2-glycoprotein I, a major target antigen of antiphospholipid antibodies: beta2-glycoprotein I interferes with binding of protein S to its plasma inhibitor, C4b-binding protein". Thromb Haemost. 81 (5): 748–57. PMID 10365749.
- ↑ Shapiro SS (1996). "The lupus anticoagulant/antiphospholipid syndrome". Annu Rev Med. 47: 533–53. doi:10.1146/annurev.med.47.1.533. PMID 8712801.
- ↑ 18.0 18.1 Male C, Mitchell L, Julian J, Vegh P, Joshua P, Adams M; et al. (2001). "Acquired activated protein C resistance is associated with lupus anticoagulants and thrombotic events in pediatric patients with systemic lupus erythematosus". Blood. 97 (4): 844–9. PMID 11159506.
- ↑ Morel O, Jesel L, Freyssinet JM, Toti F (2005). "Elevated levels of procoagulant microparticles in a patient with myocardial infarction, antiphospholipid antibodies and multifocal cardiac thrombosis". Thromb J. 3: 15. doi:10.1186/1477-9560-3-15. PMC 1266401. PMID 16219103.
- ↑ Pericleous C, Giles I, Rahman A (2009). "Are endothelial microparticles potential markers of vascular dysfunction in the antiphospholipid syndrome?". Lupus. 18 (8): 671–5. doi:10.1177/0961203309103062. PMID 19502261.
- ↑ Williams FM, Parmar K, Hughes GR, Hunt BJ (2000). "Systemic endothelial cell markers in primary antiphospholipid syndrome". Thromb Haemost. 84 (5): 742–6. PMID 11127848.
- ↑ Dignat-George F, Camoin-Jau L, Sabatier F, Arnoux D, Anfosso F, Bardin N; et al. (2004). "Endothelial microparticles: a potential contribution to the thrombotic complications of the antiphospholipid syndrome". Thromb Haemost. 91 (4): 667–73. doi:10.1160/TH03-07-0487. PMID 15045126.
- ↑ Ambrozic A, Bozic B, Kveder T, Majhenc J, Arrigler V, Svetina S; et al. (2005). "Budding, vesiculation and permeabilization of phospholipid membranes-evidence for a feasible physiologic role of beta2-glycoprotein I and pathogenic actions of anti-beta2-glycoprotein I antibodies". Biochim Biophys Acta. 1740 (1): 38–44. doi:10.1016/j.bbadis.2005.02.009. PMID 15878739.
- ↑ Brouwer JL, Bijl M, Veeger NJ, Kluin-Nelemans HC, van der Meer J (2004). "The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus". Blood. 104 (1): 143–8. doi:10.1182/blood-2003-11-4085. PMID 15026314.
- ↑ Nojima J, Kuratsune H, Suehisa E, Kawasaki T, Machii T, Kitani T; et al. (2002). "Acquired activated protein C resistance is associated with the co-existence of anti-prothrombin antibodies and lupus anticoagulant activity in patients with systemic lupus erythematosus". Br J Haematol. 118 (2): 577–83. PMID 12139749.